This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cardiovasculardisease (CVD) remains a global health burden despite advances in prevention and treatment. Conventional biomarkers, while effective for a number of patient groups, fail to provide personalized diagnosis and prognosis, necessitating the exploration of novel markers.
ABSTRACT: Albuminuria, an established biomarker of the progression of chronic kidney disease, is also recognized as a biomarker for the risk of cardiovasculardisease. There are now several therapeutic agents that can lead to albuminuria lowering and a reduction in cardiovascularrisk.
The association between iron biomarkers and cardiovasculardiseaseriskfactors (CVD-RFs) remains unclear. We aimed to (1) evaluate the cross-sectional and longitudinal associations between iron biomarkers (se.
Cardiovasculardiseases (CVD) remain the leading cause of morbidity and mortality globally. Traditional risk models, primarily based on established riskfactors, often lack the precision needed to accurately p.
This clearance comes in advance of disease-modifying therapies on the horizon expected to help clinicians use this biomarker to guide patients to improved cardiovascular health, saidBrad Moore, president and CEO at Roche Diagnostics North America. The development of the Tina-quant Lipoprotein (a) Gen.2 J Clin Lipidol.
BackgroundEmerging genetic and observational evidence indicates that remnant cholesterol (RC) is a significant residual riskfactor for cardiovasculardiseases. However, there is a relative paucity of evidence exploring the correlation among RC, lipid ratios, and atherosclerotic lesion severity.
We talk about why the ketogenic diet is helpful for people with diabetes and then dive into the details of each study to explore how 10 years on the diet affected cardiovascular health riskfactors and clinical biomarkers. Andrew posted two great threads about the papers on X. You can check those out below.
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascularriskfactors.
BACKGROUND:The relationship between marijuana use and cardiovascular health remains uncertain, with several observational studies suggesting a potential association with increased adverse atherosclerotic cardiovasculardisease (ASCVD) outcomes. Likewise, mean 10-year ASCVD risk scores (2.8% were current users. versus 2.1,P=0.89),
Here’s what you can expect at the biggest conference in cardiorenal metabolic health, the 19th Annual Cardiometabolic Congress (CMHC), DECODING THE CONSTELLATION of Cardiometabolic Health and RiskFactors. Learn more or secure your registration by clicking here.
This study sought to evaluate the prevalence of cardiovascularriskfactors, overt cardiovasculardisease and cardiac imaging abnormalities using cardiac magnetic resonance (CMR), in participants with normal LVEF on completion of trastuzumab±anthracycline therapy at least 5 years previously.
fold higher risk for cardiac mortality and 5.5-fold fold higher risk for major adverse cardiac events (MACE) Caristo's AI-Risk model, CaRi-Heart Risk Score, outperformed other scores in routine clinical use for prediction of cardiac mortality, and when presented to clinicians, resulted in changes of management decision in 45% of the patients.
Atherosclerotic coronary artery disease (CAD) is the causal pathological process driving most major adverse cardiovascular events (MACE) worldwide. The complex development of atherosclerosis manifests as intimal plaque which occurs in the presence or absence of traditional riskfactors.
Background Hepatocyte growth factor (HGF) is a biomarker with potential for use in the diagnosis, treatment and prognostication of cardiovasculardisease (CVD). We used Poisson and linear mixed-effects regression models to estimate the association between HGF and ECC, adjusted for sociodemographic and CVD riskfactors.
Hypertension is the primary modifiable riskfactor for cardiovascular, renal, and cerebrovascular diseases and is considered the main contributing factor to morbidity and mortality worldwide.
It is currently unknown if these associations are confounded by pleiotropic effects of the instrumental variables (IV) on cardiovasculardisease (CVD) riskfactors, such as low-density lipoprotein cholesterol (LDL), diastolic blood pressure (DBP), and body mass index (BMI).
There was no significant difference in history of cardiovasculardisease events (6% versus 4%, p=0.143). LV apical circumferential strain>-10% may be a novel and quantitative stroke riskfactor. Further studies are needed to validate these CMR biomarkers of stroke risk.
However Most people do not appreciate that being a carrier of APOE4 significantly increases the risk of cardiovasculardisease also. Very low levels of desmosterol, a cholesterol synthesis marker, are often lower in those with Alzheimer’s dementia, and these low levels could be seen as a riskfactor for this condition 9.
An elevated Lp(a) is a common genetic factor that is independently and causally related to premature coronary artery disease. But we must always remember that most genetic riskfactors are probabilistic rather than deterministic in terms of risk. This is the case with an elevated Lp(a). Atherosclerosis.
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Type 2 Diabetes When it comes to the increasing the risk of major chronic diseases such as cardiovasculardisease, many cancers and dementia, type 2 diabetes plays a huge role. For example, people with type 2 diabetes are 10 times more likely to develop cardiovasculardisease than those who do not have diabetes 10.
Insulin resistance is a major riskfactor for the leading causes of death, the leading one being cardiovasculardisease. Understanding where you sit on this continuum is a key part of defining your future risk of heart disease but also dementia, and many cancers. The key is to identify risk much earlier.
Clinicians currently use two separate risk models to assess patients’ chances of having heart attacks , strokes , and other major cardiovascular events. Clinicians currently use two separate risk models to assess patients’ chances of having heart attacks , strokes , and other major cardiovascular events.
February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, DAIC has compiled a snapshot of significant cardiovasculardisease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market. per 1,000* - 122.4
Cardiovasculardisease (CVD) remains the leading cause of death worldwide, imposing a major burden on morbidity, quality of life, and societal costs, making prevention of CVD a top public health priority. Extensive research has pointed out that lack of adequate physical activity in life is one of the key riskfactors for heart disease.
Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovasculardisease, type 2 diabetes, and metabolic syndrome. high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g.,
BACKGROUND:Many studies have explored whether individual plasma protein biomarkers improve cardiovasculardiseaserisk prediction. We sought to investigate the use of a plasma proteomics-based approach in predicting different cardiovascular outcomes.METHODS:Among 51 859 UK Biobank participants (mean age, 56.7
BACKGROUND:Cardiovascular disease (CVD) is among the leading causes of death worldwide. The discovery of new omics biomarkers could help to improve risk stratification algorithms and expand our understanding of molecular pathways contributing to the disease. Circulation: Genomic and Precision Medicine, Ahead of Print.
Left ventricular (LV) global longitudinal strain (GLS) assessed via feature tracking cardiac magnetic resonance imaging is associated with increased risk of major adverse cardiovascular events (MACE). LV GLS is associated with MACE in adults without prevalent cardiovasculardisease (CVD). 2.38, p = 0.04).
Insulin resistance and diabetes may not ‘ cause ’ coronary artery disease, but they are huge accelerants. In fact, when considering the contribution of risk for cardiovasculardisease, diabetes and its early manifestations, such as metabolic syndrome and insulin resistance, are some of the biggest drivers of risk.
Background Sepsis is associated with an increased risk of adverse cardiovascular events in a magnitude comparable to other major cardiovascularriskfactors. We conducted a scoping review to map existing evidence and identify research gaps relating to cardiovascular dysfunction following sepsis.
There has been considerable progress in the prevention and treatment of cardiovasculardisease, reducing the population burden of cardiovascular morbidity and mortality.
At the same time, we know that there are gender differences in health , including differences in pain perception and management, hormonal changes in brain and pain, and cardiometabolic riskfactors, among other factors contributing to the complex interplay of sex and gender in health.
Coronary artery calcium (CAC) is a measure of atherosclerosis and a strong predictor of cardiovasculardisease. While CAC is typically associated with traditional riskfactors such as age, hypertension, and smoking, paradoxically elevated CAC scores have been observed in male endurance athletes despite their otherwise healthy profiles.
Cardiovasculardisease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Moreover, cardiovasculardisease in women continues to be underrepresented and undertreated.
The hypothesis that a raised cholesterol level causes heart disease [atherosclerotic cardiovasculardisease (ASCVD)] is possibly the single most powerful idea in medicine. Which remains the single most influential study on cardiovasculardisease, ever. At least some of it. It was simply a matter of time.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content